Indication
•Treatment of all patients with type 1 diabetes.
•Treatment of patients with type 2 diabetes who are not adequately controlled by diet and/ or oral hypoglycemic agents.
•For the initial stabilization of diabetes in patients with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome and during periods of stress such as severe infections and major surgery in diabetic patients
•Treatment of gestational diabetes.
Dosage And Administration
Dosage is individual and determined by the physician in accordance with the needs of the patient. The average range of total daily insulin requirement for diabetes therapy ranges between 0.5 and 1.0 IU/Kg, dependent on the individual patients. An injection should be followed within 30 minutes by a meal or snack containing carbohydrates. It is usually administered subcutaneously in the abdominal wall. The thigh, the gluteal region or the deltoid region may also be used. Subcutaneous injection into the abdominal wall ensures a faster absorption than from other injection sites.In order to avoid lipodystrophy, injection sites for a given insulin preparation should be rotated within an anatomic region.
Side Effects
Adverse drug reactions observed in patients using human insulin are mainly dose-dependent and due to the pharmacologic effect of insulin. As for other insulin products, hypoglycemia, in general is the most frequently undesirable effect. It may occur if the insulin dose is too high in relation to the insulin requirement. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area. Symptoms of generalized hypersensitivity may include generalized skin rash, itching, sweating, gastrointestinal upset and angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure. Generalised hypersensitivity reactions are potentially life threatening. Oedema may occur upon initiation of insulin therapy. These symptoms are usually of transitory nature.
Reviews
There are no reviews yet.